Abstract
Background:
Sciatic nerve ligation causes neuropathic pain with chronic constriction injury (CCI). However, there is no published report on the effect of pioglitazone as an antidepressant in the treatment of depression induced by neuropathic pain with CCI in rats. The aim of this study was to evaluate the effect of pioglitazone as an antidepressant by targeting oxidative stress by the peripheral neuropathic pain model using the CCI of the sciatic nerve.
Methods:
Behavioral studies were carried out to measure thermal hyperalgesia and cold allodynia as markers of neuropathic pain and force swim test for depression. These were followed by estimation of biochemical parameters which include lipid peroxidation (LPO), reduced glutathione, catalase, nitrite and superoxide dismutase (SOD) in the rat brains as a measure of oxidative stress. We administered two intraperitoneal doses of pioglitazone (4.5 and 9.0 mg/kg, i.p.) to the treated group for 28 consecutive days from the day of injury and behavioral as well as biochemical evaluations were performed.
Results:
The results suggested that the administration of pioglitazone significantly countered the neuropathic pain induced depression as interpreted through elevated pain threshold of tactile allodynia and thermal hyperalgesia followed by decreased immobility time in the 9.0 mg/kg dose group.
Conclusions:
It may be concluded that the oxidative stress plays a critical role in the pathogenesis of neuropathic pain and depression as evidenced by the behavioral studies and the changes in the levels of lipid peroxidase, nitrite, catalase, and glutathione and SOD.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Authier N, Fialip J, Eschalier A, Coudoré F. Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neurosci Lett 2000;291:73–6.10.1016/S0304-3940(00)01373-2Search in Google Scholar PubMed
2. Lynch ME, Watson CP. The pharmacotherapy of chronic pain: a review. Pain Res Manag 2006;11:11–38.10.1155/2006/642568Search in Google Scholar PubMed
3. Demyttenaere K, Bruffaerts R, Lee S, Posada-Villa J, Kovess V, Angermeyer MC, et al. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain 2007;129:332–42.10.1016/j.pain.2007.01.022Search in Google Scholar PubMed
4. Lépine JP, Briley M. The epidemiology of pain in depression. Human Psychopharmacol: Clin Exp 2004;19(S1).10.1002/hup.618Search in Google Scholar
5. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001;413:203.10.1038/35093019Search in Google Scholar PubMed
6. Jensen TS, Gottrup H, Sindrup SH, Bach FW. The clinical picture of neuropathic pain. Eur J Pharmacol 2001;429:1–11.10.1016/S0014-2999(01)01302-4Search in Google Scholar PubMed
7. Rudy TE, Kerns RD, Turk DC. Chronic pain and depression: toward a cognitive-behavioral mediation model. Pain 1988;35:129–40.10.1016/0304-3959(88)90220-5Search in Google Scholar
8. Doan BD, Wadden NP. Relationships between depressive symptoms and descriptions of chronic pain. Pain 1989;36:75–84.10.1016/0304-3959(89)90113-9Search in Google Scholar PubMed
9. Banks SM, Kerns RD. Explaining high rates of depression in chronic pain: a diathesis-stress framework. Psychol Bull 1996;119:95.10.1037/0033-2909.119.1.95Search in Google Scholar
10. Blackburn-Munro G. Hypothalamo-pituitary-adrenal axis dysfunction as a contributory factor to chronic pain and depression. Curr Pain Headache Rep 2004;8:116–24.10.1007/s11916-004-0025-9Search in Google Scholar PubMed
11. Chappell AS, Desaiah D, Liu-Seifert H, Zhang S, Skljarevski V, Belenkov Y, et al. A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Practice 2011;11:33–41.10.1111/j.1533-2500.2010.00401.xSearch in Google Scholar
12. Maeda T, Kiguchi N, Kobayashi Y, Ozaki M, Kishioka S. Pioglitazone attenuates tactile allodynia and thermal hyperalgesia in mice subjected to peripheral nerve injury. J Pharmacol Sci 2008;108:341–7.10.1254/jphs.08207FPSearch in Google Scholar PubMed
13. McIntyre RS, Soczynska JK, Woldeyohannes HO, Lewis GF, Leiter LA, MacQueen GM, et al. Thiazolidinediones: novel treatments for cognitive deficits in mood disorders? Expert Opin Pharmacother 2007;8:1615–28.10.1517/14656566.8.11.1615Search in Google Scholar PubMed
14. Rosa AO, Kaster MP, Binfare RW, Morales S, Martin-Aparicio E, Navarro-Rico ML, et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatr 2008;32:1549–56.10.1016/j.pnpbp.2008.05.020Search in Google Scholar
15. Gold PW, Licinio J, Pavlatou MG. Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR-[gamma] systems. Mol Psychiatr 2013;18:154.10.1038/mp.2012.167Search in Google Scholar
16. Bennett GJ, Xie YK. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87–107.10.1016/0304-3959(88)90209-6Search in Google Scholar PubMed
17. Kumar A, Meena S, Kalonia H, Gupta A, Kumar P. Effect of nitric oxide in protective effect of melatonin against chronic constriction sciatic nerve injury induced neuropathic pain in rats. Ind J Exp Biol 2011;49:664–71.Search in Google Scholar
18. Osikowicz M, Mika J, Makuch W, Przewlocka B. Glutamate receptor ligands attenuate allodynia and hyperalgesia and potentiate morphine effects in a mouse model of neuropathic pain. Pain 2008;139:117–26.10.1016/j.pain.2008.03.017Search in Google Scholar
19. Ghasemi M, Montaser-Kouhsari L, Shafaroodi H, Nezami BG, Ebrahimi F, Dehpour AR. NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology 2009;206:325–33.10.1007/s00213-009-1609-1Search in Google Scholar PubMed
20. Wills ED. Mechanisms of lipid peroxide formation in animal tissues. Biochem J 1966;99:667–76.10.1042/bj0990667Search in Google Scholar PubMed
21. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 1982;126:131–8.10.1016/0003-2697(82)90118-XSearch in Google Scholar PubMed
22. Luck H. Catalase. In: Bergmeyer HU, editor. Methods of enzymatic analysis. New York: Academic Press, 1971:885–93.10.1016/B978-0-12-395630-9.50158-4Search in Google Scholar
23. Kono Y. Generation of superoxide radical during auto-oxidation of hydroxylamine and an assay of superoxide dismutase. Arch Biochem Biophys 1978;186:189–95.10.1016/0003-9861(78)90479-4Search in Google Scholar
24. Dworkin RH, O’Connor AB, Audette J, Baron R, Gourlay GK, Haanpaa ML, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85:S3–14.10.4065/mcp.2009.0649Search in Google Scholar PubMed PubMed Central
25. Surah A, Baranidharan G, Morley S. Chronic pain and depression. Continuing Education in Anaesthesia, Critical Care & Pain. 2014;14:85–89.10.1093/bjaceaccp/mkt046Search in Google Scholar
26. Chen NS, Chen YC, Yeh TC. Efficacy of pregabalin augmentation for refractory pain in late-life depression. Aust NZ J Psychiatr 2017;51:413–4.10.1177/0004867416664141Search in Google Scholar PubMed
27. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805–15.10.1213/01.ane.0000287643.13410.5eSearch in Google Scholar PubMed
28. Berlin RK, Butler PM, Perloff MD. Gabapentin therapy in psychiatric disorders: a systematic review. Prim Care Companion CNS Disord 2015;17:10.4088/PCC.15r01821.10.4088/PCC.15r01821Search in Google Scholar PubMed PubMed Central
29. Kukkar A, Bali A, Singh N, Jaggi AS. Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res 2013;36:237–51.10.1007/s12272-013-0057-ySearch in Google Scholar PubMed
30. Guedes RP, Araujo AS, Janner D, Bello-Klein A, Ribeiro MF, Partata WA. Increase in reactive oxygen species and activation of Akt signaling pathway in neuropathic pain. Cell Mol Neurobiol 2008;28:1049–56.10.1007/s10571-008-9279-9Search in Google Scholar PubMed
31. Okami N, Narasimhan P, Yoshioka H, Sakata H, Kim GS, Jung JE, et al. Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase. J Cereb Blood Flow Metab 2013;33:106–14.10.1038/jcbfm.2012.138Search in Google Scholar PubMed PubMed Central
32. Pathan AR, Viswanad B, Sonkusare SK, Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 2006;79:2209–16.10.1016/j.lfs.2006.07.018Search in Google Scholar PubMed
33. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain 2000;87:149–58.10.1016/S0304-3959(00)00276-1Search in Google Scholar PubMed
34. Bennett GJ, Xie YK. A peripheral mononeuropathy in rats that produces disorder of pain sensation in rats like those seen in man. Pain 1988;33:87–107.10.1016/0304-3959(88)90209-6Search in Google Scholar
35. Moalem G, Tracey DJ. Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev 2006;51:240–64.10.1016/j.brainresrev.2005.11.004Search in Google Scholar PubMed
36. Naik AK, Tandan SK, Dudhgaonkar SP, Jadhav SH, Kataria M, Prakash VR, et al. Role of oxidative stress in pathophysiology of peripheral neuropathy and modulation by N-acetyl-L-cysteine in rats. Eur J Pain 2006;10:573–9.10.1016/j.ejpain.2005.08.006Search in Google Scholar PubMed
37. Wang J, Goffer D, Xu DS, Tukey DB, Shamir SE, Eberle AH, et al. Single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology 2011;115:812–21.10.1097/ALN.0b013e31822f16aeSearch in Google Scholar PubMed PubMed Central
38. Gerrits MM, Vogelzangs N, Van Oppen P, Van Marwijk HW, van der Horst H, Penninx BW. Impact of pain on the course of depressive and anxiety disorders. Pain 2012;153:429–36.10.1016/j.pain.2011.11.001Search in Google Scholar PubMed
39. Maria Michel T, Pulschen D, Thome J. The role of oxidative stress in depressive disorders. Curr Pharm Des 2012;18:5890–9.10.2174/138161212803523554Search in Google Scholar PubMed
40. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R. Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 2003;8:365–70.10.1179/135100003225003393Search in Google Scholar PubMed
41. Chung CP, Schmidt D, Stein CM, Morrow JD, Salomon RM. Increased oxidative stress in patients with depression and its relationship to treatment. Psychiatr Res 2013;206: 213–6.10.1016/j.psychres.2012.10.018Search in Google Scholar PubMed PubMed Central
©2017 Walter de Gruyter GmbH, Berlin/Boston
